摘要: … The overall 5-year survival rate for patients with metastatic colorectal cancer (CRC) is less … Current standard first-line regimens for metastatic CRC are FOLFOX (infusional 5-FU/LV with …
elsevier.com
oup.com
sci-hub.se 参考文章(98)
M. G. Zampino, K. Lorizzo, C. Massacesi, A. Rizzi, S. Crispino, S. Boselli, G. Pelosi, L. Zorzino, N. Fazio, F. de Braud, First-line gefitinib combined with simplified FOLFOX-6 in patients with epidermal growth factor receptor-positive advanced colorectal cancer Journal of Clinical Oncology. ,vol. 23, pp. 3659- 3659 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.3659
Rainer Porschen, Andreas Bermann, Thomas Löffler, Gregor Haack, Klaus Rettig, Yvonne Anger, Georg Strohmeyer, Fluorouracil Plus Leucovorin as Effective Adjuvant Chemotherapy in Curatively Resected Stage III Colon Cancer: Results of the Trial adjCCA-01 Journal of Clinical Oncology. ,vol. 19, pp. 1787- 1794 ,(2001) , 10.1200/JCO.2001.19.6.1787
J Tol, M Koopman, NF Antonini, H Sinnige, FAA Valster, JJ Braun, AJ ten Tije, L Mol, JHJM van Krieken, C Punt, Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) Journal of Clinical Oncology. ,vol. 26, ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.LBA4011
Norman Wolmark, Howard Rockette, Eleftherios Mamounas, Judy Jones, Sam Wieand, DL Wickerham, Harry D Bear, James N Atkins, Nikolay V Dimitrov, Andrew G Glass, Edwin R Fisher, Bernard Fisher, None, Clinical Trial to Assess the Relative Efficacy of Fluorouracil and Leucovorin, Fluorouracil and Levamisole, and Fluorouracil, Leucovorin, and Levamisole in Patients With Dukes' B and C Carcinoma of the Colon: Results From National Surgical Adjuvant Breast and Bowel Project C-04 Journal of Clinical Oncology. ,vol. 17, pp. 3553- 3559 ,(1999) , 10.1200/JCO.1999.17.11.3553
E Gamelin, M Boisdron-Celle, R Delva, C Regimbeau, P E Cailleux, C Alleaume, M L Maillet, M J Goudier, M Sire, M C Person-Joly, M Maigre, P Maillart, R Fety, P Burtin, A Lortholary, Y Dumesnil, L Picon, J Geslin, P Gesta, E Danquechin-Dorval, F Larra, J Robert, Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. Journal of Clinical Oncology. ,vol. 16, pp. 1470- 1478 ,(1998) , 10.1200/JCO.1998.16.4.1470
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. Journal of Clinical Oncology. ,vol. 22, pp. 3766- 3775 ,(2004) , 10.1200/JCO.2004.03.104
C. Bokemeyer, I. Bondarenko, J. T. Hartmann, F. G. De Braud, C. Volovat, J. Nippgen, C. Stroh, I. Celik, P. Koralewski, KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience Journal of Clinical Oncology. ,vol. 26, pp. 4000- 4000 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.4000
G Milano, M C Etienne, N Renée, A Thyss, M Schneider, A Ramaioli, F Demard, Relationship between fluorouracil systemic exposure and tumor response and patient survival. Journal of Clinical Oncology. ,vol. 12, pp. 1291- 1295 ,(1994) , 10.1200/JCO.1994.12.6.1291
Paulo M. Hoff, Rafat Ansari, Gerald Batist, John Cox, Walter Kocha, Mario Kuperminc, Jean Maroun, David Walde, Charles Weaver, Evelyn Harrison, Hans U. Burger, Bruno Osterwalder, Alfred O. Wong, Ralf Wong, Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study Journal of Clinical Oncology. ,vol. 19, pp. 2282- 2292 ,(2001) , 10.1200/JCO.2001.19.8.2282
P G Johnston, S Kaye, Capecitabine: a novel agent for the treatment of solid tumors. Anti-Cancer Drugs. ,vol. 12, pp. 639- 646 ,(2001) , 10.1097/00001813-200109000-00001